# Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

> **NCT04319783** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Trans Tasman Radiation Oncology Group** · enrollment: 65 (actual)

## Conditions studied

- Advanced Prostate Carcinoma
- Cancer of Prostate
- PSA
- Castrate Resistant Prostate Cancer

## Interventions

- **DRUG:** Darolutamide
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT04319783
- **Lead sponsor:** Trans Tasman Radiation Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-02
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2025-08-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04319783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04319783, "Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04319783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*